Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration

Cancer Letters

Volumn 370, Issue 1, 2016, Pages 66-77

  Yeh, Poh Shiow ^a,b   Wang, Weu ^c   Chang, Ya An ^d   Lin, Chien Ju ^d   Wang, Jhi Joung ^a   Chen, Ruei Ming ^b,c,d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Autophagy; Cell migration; Honokiol; Mechanisms; Neuroblastoma

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 METHYLADENINE; ACETYLCYSTEINE; GLUCOSE REGULATED PROTEIN 78; HONOKIOL; MAMMALIAN TARGET OF RAPAMYCIN; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3 II; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; LIGNAN; MITOGEN ACTIVATED PROTEIN KINASE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG EXPOSURE; ENDOPLASMIC RETICULUM STRESS; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; INCUBATION TIME; MIGRATION INHIBITION; NB41A3 CELL LINE; NEURO 2A CELL LINE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR NECROSIS; ANIMAL; CELL MOTION; DRUG EFFECTS; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AUTOPHAGY; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL MOVEMENT; ENDOPLASMIC RETICULUM STRESS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIGNANS; MICE; NEUROBLASTOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84949481132     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.08.030     Document Type: Article

References (54)

1. Jvan der Pal H., van Dalen E.C., Kremer L.C., Bakker P.J., van Leeuwen F.E. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. Cancer Treat. Rev 2005, 31:173-185.
2. Hoehner J.C., Gestblom C., Hedborg F., Sandstedt B., Olsen L., Påhlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab. Invest 1996, 75:659-675.
3. Morandi F., Corrias M.V., Pistoia V. Evaluation of bone marrow as a metastatic site of human neuroblastoma. Ann. N. Y. Acad. Sci 2015, 1335:23-31.
4. Park J.R., Eggert A., Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr. Clin. North Am 2008, 55:97-120.
5. DuBois S.G., Kalika Y., Lukens J.N., Brodeur G.M., Seeger R.C., Atkinson J.B., et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J. Pediatr. Hematol. Oncol 1999, 21:181-189.
6. Pearson A.D., Pinkerton C.R., Lewis I.J., Imeson J., Ellershaw C., Machin D. European neuroblastoma study group, children's cancer and leukaemia group (CCLG formerly United Kingdom Children's Cancer Study Group). High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008, 9:247-256.
7. Wagner L.M., Danks M.K. New therapeutic targets for the treatment of high-risk neuroblastoma. J. Cell. Biochem 2009, 107:46-57.
8. Zage P.E., Kletzel M., Murray K., Marcus R., Castleberry R., Zhang Y., et al. Children's oncology group, outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr. Blood Cancer 2008, 51:747-753.
9. Lo Y.C., Teng C.M., Chen C.F., Chen C.C., Hong C.Y. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem. Pharmacol 1994, 47:549-553.
10. Esumi T., Makado G., Zhai H., Shimizu Y., Mitsumoto Y., Fukuyama Y. Efficient synthesis and structure-activity relationship of honokiol, a neurotrophic biphenyl-type neolignan. Bioorg. Med. Chem. Lett 2004, 14:2621-2625.
11. Fried L.E., Arbiser J.L. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid. Redox Signal 2009, 11:1139-1148.
12. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N. Engl. J. Med 1999, 341:1165-1173.
13. Kotani H., Tanabe H., Mizukami H., Makishima M., Inoue M. Identification of a naturally occurring rexinoid, honokiol that activates the retinoid X receptor. J. Nat. Prod 2010, 73:1332-13326.
14. Chen J., Costa L.G., Guizzetti M. Retinoic acid isomers up-regulate ATP binding cassette A1 and G1 and cholesterol efflux in rat astrocytes: implications for their therapeutic and teratogenic effects. J. Pharmacol. Exp. Therap 2011, 338:3870-3878.
15. Zhai H., Nakade K., Oda M., Mitsumoto Y., Akagi M., Sakurai J., et al. Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2). Eur. J. Pharmacol 2005, 516:112-117.
16. Lin Y.R., Chen H.H., Ko C.H., Chan M.H. Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. Eur. J. Pharmacol 2006, 537:64-69.
17. Arora S., Singh S., Piazza G.A., Contreras C.M., Panyam J., Singh A.P. Honokiol: a novel natural agent for cancer prevention and therapy. Curr. Mol. Med 2012, 12:1244-1252.
18. Lin J.W., Chen J.T., Hong C.Y., Lin Y.L., Wang K.T., Yao C.J., et al. Honokiol traverses the blood-brain barrier and induces apoptosis of neuroblastoma cells via an intrinsic Bax-mitochondrion-cytochrome c-caspase protease pathway. Neuro-Oncol 2012, 14:302-314.
19. Grimmel M., Backhaus C., Proikas-Cezanne T. WIPI-mediated autophagy and longevity. Cells 2015, 4:202-217.
20. Jaeger P.A., Wyss-Coray T. All-you-can-eat: autophagy in neurodegeneration and neuroprotection. Mol. Neurodegener 2009, 4:16.
21. Kanazawa T., Bedwell J., Kondo Y., Kondo S., Germano I.M. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J. Neurosurg 2003, 99:1047-1052.
22. Kim K.C., Guan K.L. mTOR: a pharmacologic target for autophagy regulation. J. Clin. Invest 2015, 125:25-32.
23. Vakifahmetoglu-Norberg H., Xia H.G., Yuan J. Pharmacologic agents targeting autophagy. J. Clin. Invest 2015, 125:5-13.
24. Zhang L., Lee K.C., Bhojani M.S., Khan A.P., Shilman A., Holland E.C., et al. Molecular imaging of Akt kinase activity. Nat. Med 2007, 13:1114-1119.
25. Cheng P., Ni Z., Dai X., Wang B., Ding W., Rae Smith A., et al. The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular carcinoma cells. Cell Death Dis 2013, 4:e598.
26. Hoyer-Hansen M., Jaattela M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ 2007, 14:1576-1582.
27. Rzymski T., Petry A., Kracun D., Ries F., Pike L., Harris A.L., et al. The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene 2012, 31:3621-3634.
28. Chang C.Y., Lui T.N., Lin J.W., Lin Y.L., Hsing C.H., Wang J.J., et al. Roles of microRNA-1 in hypoxia-induced apoptotic insults to neural cells. Arch. Toxicol 2015, 10.1007/s00204-014-1364-x.
29. L gene expression. J. Bone Miner. Res 2010, 25:2193-2204.
30. L gene expression and protein translocation. Arch. Toxicol 2015, 10.1007/s00204-015-1491-z.
31. Chang K.H., Yan M.D., Yao C.J., Lin P.C., Lai G.M. Honokiol-induced apoptosis and autophagy in glioblastoma multiforme cells. Oncol. Lett 2013, 6:1435-1438.
32. Chuang C.Y., Chen T.L., Cherng Y.G., Tai Y.T., Chen T.G., Chen R.M. Lipopolysaccharide induces apoptotic insults to human alveolar epithelial A549 cells through reactive oxygen species-mediated activation of an intrinsic mitochondrion-dependent pathway. Arch. Toxicol 2011, 85:209-218.
33. Chio C.C., Lin J.W., Cheng H.A., Chiu W.T., Wang Y.H., Wang J.J., et al. MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Arch. Toxicol 2013, 87:458-468.
34. Gupta A., Williams B.R., Hanash S.M., Rawwas J. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma. Cancer Res 2006, 66:8100-8108.
35. Knaevelsrud H., Carlsson S.R., Simonsen A. SNX18 tubulates recycling endosomes for autophagosome biogenesis. Autophagy 2013, 9:1639-1641.
36. Sieber F., Sieber-Blum M. Dye-mediated photosensitization of murine neuroblastoma cells. Cancer Res 1986, 46:2072-2076.
37. Wu Y.T., Tan H.L., Shui G., Bauvy C., Huang Q., Wenk M.R., et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J. Biol. Chem 2010, 285:10850-10861.
38. Lv X., Liu F., Shang Y., Chen S.Z. Honokiol exhibits enhanced antitumor effects with chloroquine by inducing cell death and inhibiting autophagy in human non-small cell lung cancer cells. Oncol. Rep 2015, 34:1289-1300.
39. Kaushik G., Venugopal A., Ramamoorthy P., Standing D., Subramaniam D., Umar S., et al. Honokiol inhibits melanoma stem cells by targeting notch signaling. Mol. Carcinog 2014, 10.1002/mc.22242.
40. Hahm E.R., Sakao K., Singh S.V. Honokiol activates reactive oxygen species-mediated cytoprotective autophagy in human prostate cancer cells. Prostate 2014, 74:1209-1221.
41. Guo Y.B., Bao X.J., Xu S.B., Zhang X.D., Liu H.Y. Honokiol induces cell cycle arrest and apoptosis via p53 activation in H4 human neuroglioma cells. Int. J. Clin. Exp. Med 2015, 15:7168-7175.
42. Hahm E.R., Singh S.V. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol. Cancer Ther 2007, 6:2686-2695.
43. Sahu U., Sidhar H., Ghate P.S., Advirao G.M., Raghavan S.C., Giri R.K. A novel anticancer agent, 8-methoxypyrimido[4',5':4,5]thieno(2,3-b) quinoline-4(3H)-one induces neuro 2a neuroblastoma cell death through p53-dependent, caspase-dependent and -independent apoptotic pathways. PLoS ONE 2013, 8:e66430.
44. Lin Y.L., Chang H.C., Chen T.L., Chang J.H., Chiu W.T., Lin J.W., et al. Resveratrol protects against oxidized LDL-induced breakage of the blood-brain barrier by lessening disruption of tight junctions and apoptotic insults to mouse cerebrovascular endothelial cells. J. Nutr 2010, 140:2187-2192.
45. Mariño G., Niso-Santano M., Baehrecke E.H., Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nature Rev. Mol. Cell Bio 2014, 15:81-94.
46. Sui X., Chen R., Wang Z., Huang Z., Kong N., Zhang M., et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 2013, 4:e838.
47. Chang H.C., Chen T.G., Tai Y.T., Chen T.L., Chiu W.T., Chen R.M. Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells. J. Cereb. Blood Flow Metab 2011, 31:842-854.
48. Laplante M., Sabatini D.M. mTOR signaling at a glance. J. Cell Sci 2009, 122:3589-3594.
49. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat 2008, 11:32-50.
50. Crane C., Panner A., Pieper R.O., Arbiser J., Parsa A.T. Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J. Immunother 2009, 32:585-592.
51. Baumeister P., Luo S., Skarnes W.C., Sui G., Seto E., Shi Y., et al. Endoplasmic reticulum stress induction of the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol. Cell. Biol 2005, 25:4529-4540.
52. Liu S.H., Lee W.J., Lai D.W., Wu S.M., Liu C.Y., Tien H.R., et al. Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress and inhibiting epithelial-to-mesenchymal transition. Mol. Oncol 2015, 9:834-849.
53. Zhu W., Fu A., Hu J., Wang T., Luo Y., Peng M., et al. 5-Formylhonokiol exerts anti-angiogenesis activity via inactivating the ERK signaling pathway. Exp. Mol. Med 2011, 43:146-152.
54. Avtanski D.B., Nagalingam A., Kuppusamy P., Bonner M.Y., Arbiser J.L., Saxena N.K., et al. Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner. Oncotarget 2015, pmid:26036628.